Massive Transfusion in Trauma Patient Registry
Launched by METHODIST HEALTH SYSTEM · Nov 13, 2023
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
The Massive Transfusion in Trauma Patient Registry is a clinical trial that aims to understand how the early use of blood products affects patients who have experienced severe injuries. This study is particularly interested in how these blood products, part of what's called a Massive Transfusion Protocol (MTP), might lead to low calcium levels in the blood, which can complicate the body's ability to form clots and stop bleeding.
To participate in this trial, individuals must be at least 18 years old and have been included in the trauma registry at Methodist Dallas Medical Center. They should also have received at least one unit of blood within the first 24 hours after their injury. Participants can expect to provide information about their treatment and recovery, helping researchers learn more about the effects of blood transfusions in trauma cases. This study is currently recruiting participants of all genders, and it’s an important step towards improving care for future trauma patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • ≥18 years old
- • Included in the Methodist dallas medical center(MDMC) trauma registry
- • Flagged for MTP activation and/or \>1unit(U) blood product recorded in the first 24 hours
- Exclusion Criteria:
- • • \<18 years old
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Conner McDaniel, MD
Principal Investigator
Methodist Midlothian Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported